Delving into the Latest Updates on CDO-7N-1 with Synapse

Overview

Basic Info

Drug Type

Live attenuated vaccine, Prophylactic vaccine

Synonyms-

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

COVID-19

Inactive Indication-

Originator Organization

Indian Immunologicals Ltd.

Active Organization

Indian Immunologicals Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Author: Gorriparthi, Sambaiah ; Lingala, Rajendra ; Cheng, Samuel M S ; Lello, Laura Sandra ; Ng, Wern Hann ; Sarkar, Sanjay ; Aavula, Shukra Madhaha ; Bonda, Rama Lakshmi ; Taylor, Adam ; Freitas, Joseph ; Dua, Ujjwal ; Heise, Mark T ; Ashhurst, Thomas M ; Mahalingam, Suresh ; Peiris, Malik ; Baric, Ralph S ; Kanakasapapathy, Anand Kumar ; Ling, Zheng L ; Taft-Benz, Sharon A ; Mani, Priyanka ; Pattnaik, Priyabrata ; Baxter, Victoria K ; Merits, Andres ; King, Nicholas J C ; Zusinaite, Eva ; Nimmagadda, Sridevi V ; Zaid, Ali ; Anderson, Elizabeth ; Yerragunta, Venugopal ; Wang, Sainan ; Liu, Xiang ; Ponsekaran, Santhakumar ; Burt, Felicity J

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) continues its significant health and economic impact globally. Despite the success of spike-protein vaccines in preventing severe disease, long-lasting protection against emerging variants and the prevention of breakthrough infections and transmission remain elusive. We generate an intranasal live-attenuated SARS-CoV-2 vaccine, CDO-7N-1, using codon deoptimization. CDO-7N-1 shows highly attenuated replication and minimal or no lung pathology in vivo over multiple passages. It induces robust mucosal and systemic neutralizing antibody and T-cell subset responses, in mice (female K18-hACE2 and male HFH4-hACE2 mice), hamsters, and macaques triggered by a single immunization. Mice and hamsters vaccinated with CDO-7N-1 are protected from challenge with wild-type (WT) SARS-CoV-2 and other variants of concern. Serum from vaccinated animals neutralizes WT SARS-CoV-2, variants of concern (beta and delta), variants of interest (omicron XBB.1.5) and SARS-CoV-1. Antibody responses are sustained and enhanced by repeated immunization or infection with WT SARS-CoV-2. Immunity against all SARS-CoV-2 proteins by CDO-7N-1 should improve efficacy against future SARS-CoV-2 variants.

100 Deals associated with CDO-7N-1

Login to view more data